Englewood Cliffs, NJ, November 28, 2017 - Dynamk Capital, a recently launched life sciences venture capital fund, today announced an exciting new investment in early drug discovery by adding Envisagenics, Inc. to its growing portfolio.
Dynamk Capital invested $500,000 in Envisagenics, leading the $2.25 million seed round alongside other investors. Envisagenics, a life science company applies artificial intelligence to the genetic sequence of patients to discover new therapies. Its proprietary cloud-based discovery platform SpliceCoreTM uses machine learning to prioritize new drug target candidates from patients’ RNA.
Daniella Kranjac, co-founder and managing director of Dynamk Capital, said, “Envisagenics is disrupting traditional drug discovery through applied machine learning and AI. We are excited to see the commercialization of SpliceCore enable biopharma leaders to accelerate critical discovery efforts for life-saving therapeutics.”